From the Chairman/CEO
Each day, millions of people struggle with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work sleep disorder -- also known as shift work disorder (SWD) -- and narcolepsy. These are serious and chronic medical conditions that impair the body's ability to stay awake, stay alert, and function.
Cephalon first recognized the breadth of this medical need more than a decade ago, when we introduced the first, new FDA-approved treatment for patients with excessive sleepiness associated with narcolepsy in 40 years. We remain committed to those patients, to the sleep community, and to developing medicines that provide true patient value.
Today, we are proud to introduce NUVIGIL® (armodafinil) Tablets (C-IV), a once-daily, longer-lasting formulation of modafinil. NUVIGIL was scientifically designed with the potential to keep patients awake for longer periods of time throughout the day.
We are Cephalon
A global biopharmaceutical company driven to expand the boundaries of science to improve human health. A company with first-in-class therapeutics, a rich oncology research pipeline and medications to treat central nervous system disorders, cancer, and pain. A company dedicated to our patients, healthcare professionals, employees, and communities.
Now Available! Cephalon Launches NUVIGIL in the US. For more information, please visit www.NUVIGIL.com.
Our Scientists
Meet the scientists at Cephalon, who transform scientific passion into clinical promise. Read more >>